... of the eye, and in July was approved to treat a related sight-robbing condition called diabetic macular edema. Tarrytown, New York-based Regeneron said it expected net sales of Eylea to be 25 percent to 30 percent higher this year than in 2014, when ...
http://ift.tt/1z46Tzj
http://ift.tt/1z46Tzj
No comments:
Post a Comment